Stock Research: Merck (USA)

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Merck (USA)

NYSE:MRK US58933Y1055
61
  • Value
    53
  • Growth
    35
  • Safety
    Safety
    90
  • Combined
    75
  • Sentiment
    42
  • 360° View
    360° View
    61
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Merck & Co., Inc. is a global healthcare company providing health solutions through prescription medicines, vaccines, and animal health products. It operates in the pharmaceutical and animal health industries. The company sells its products globally. In the last fiscal year, the company had a market cap of $204699 million, profits of $49470 million, revenue of $64168 million, and 75000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock Merck (USA) are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Merck (USA). The consolidated Value Rank has an attractive rank of 90, which means that the share price of Merck (USA) is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 90% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 53. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 42. Professional investors are more confident in 58% other stocks. The consolidated Growth Rank also has a low rank of 35, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 65 of its competitors have better growth. ...read more

more
Index
Dow Jones
Dividends USA
Diversity USA
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
90 84 60 81
Growth
35 39 43 59
Safety
Safety
53 42 46 94
Sentiment
42 34 88 96
360° View
360° View
61 28 73 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
24 39 57 27
Opinions Change
53 15 50 83
Pro Holdings
n/a 86 96 96
Market Pulse
35 37 74 72
Sentiment
42 34 88 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
90 84 60 81
Growth
35 39 43 59
Safety Safety
53 42 46 94
Combined
75 47 44 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
74 77 65 88
Price vs. Earnings (P/E)
38 32 24 36
Price vs. Book (P/B)
30 32 10 12
Dividend Yield
98 96 89 94
Value
90 84 60 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
42 49 56 51
Profit Growth
50 56 10 62
Capital Growth
46 40 56 32
Stock Returns
25 27 59 73
Growth
35 39 43 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
40 31 45 34
Refinancing
23 10 23 95
Liquidity
89 94 82 89
Safety Safety
53 42 46 94

Similar Stocks

Discover high‑ranked alternatives to Merck (USA) and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.